Introduction
============

The open angle glaucomas are chronic and progressive optic neuropathies, which have in common characteristic morphological changes at the optic nerve head and retinal nerve fiber layer in the absence of other ocular disease or congenital anomalies. Progressive retinal ganglion cell death and visual field loss are associated with these findings.[@b1-opth-8-1819] Primary open-angle glaucoma (POAG) is the most common type of glaucoma. Intraocular pressure and other currently unknown factors contribute to the optic nerve damage. There is increasing evidence that anatomic or functional abnormalities of the optic nerve head vessels compromising the microcirculation and perfusion might play a role in the pathogenesis of the disease.[@b2-opth-8-1819]--[@b4-opth-8-1819]

Pseudoexfoliation is an age-related ocular clinical entity, and is strongly associated with development of glaucoma (pseudoexfoliation glaucoma \[PXFG\]).[@b5-opth-8-1819] It is characterized by accumulation of fibrinous, flake-shaped material in ocular tissues, especially in the anterior chamber of the eye. Higher intraocular pressure and the presence of disc hemorrhages were reported to be independent risk factors for progression of PXFG.[@b6-opth-8-1819] With the use of electron microscopy methods, several investigators have detected exfoliation material in the extraocular tissue as well, suggesting that exfoliation might be the ocular manifestation of a systemic disorder.[@b7-opth-8-1819],[@b8-opth-8-1819] A number of systemic vascular disorders, including stroke, acute myocardial infarction, and aneurysms of the abdominal aorta were found to be associated with ocular exfoliation.[@b9-opth-8-1819],[@b10-opth-8-1819]

Hyperhomocysteinemia is a known risk factor for vascular disease, including brain and heart infarction,[@b11-opth-8-1819],[@b12-opth-8-1819] as well as retinal vascular occlusions.[@b13-opth-8-1819]--[@b15-opth-8-1819] Based on the hypothesis that vascular dysfunction is one of the factors involved in the pathogenesis of glaucoma,[@b2-opth-8-1819]--[@b4-opth-8-1819],[@b16-opth-8-1819] homocysteine was studied in several POAG and PXFG cohorts. Increased serum and tear homocysteine levels were found to be present in patients with POAG.[@b17-opth-8-1819],[@b18-opth-8-1819] Elevated plasma homocysteine levels have also been found in patients with PXFG,[@b19-opth-8-1819],[@b20-opth-8-1819] and these findings were recently confirmed by two published meta-analyses.[@b21-opth-8-1819],[@b22-opth-8-1819] The genetic component of circulating homocysteine involves single nucleotide polymorphisms on five genes, ie, *methylenetetrahydrofolate reductase* (*MTHFR*), methionine synthase, methionine synthase reductase, *methylenetetrahydrofolate dehydrogenase* (*MTHFD1*), and cystathionine β-synthase, encoding enzymes within the pathway of homocysteine metabolism on chromosomes 1, 5, 14, and 21. Some of these single nucleotide polymorphisms have been studied in connection with glaucoma, but none has been shown to have a statistically significant correlation.[@b23-opth-8-1819]--[@b26-opth-8-1819] Two of the genetic variants (rs1801133 and rs1801131) are located in two exons of the *MTHFR* gene on chromosome 1. rs1801133 is a C\>T missense variation, leading to increased thermolability and reduced activity of the MTHFR enzyme and rs1801131 is an A\>C missense variation on the same gene.[@b27-opth-8-1819] rs8006686 is an intron T\>C polymorphism of the *MTHFD1* enzyme gene on chromosome 14. In a study by Fan et al the rs8006686 polymorphism showed a marginally significant association with PXFG, but this finding was not stable after correction for multiple comparisons.[@b23-opth-8-1819]

Materials and methods
=====================

This was a prospective, case-control association study that assessed plasma homocysteine levels and genetic variants of homocysteine metabolism enzymes in a cohort of Greek patients with either POAG or PXFG as compared with controls. In order to determine the impact of homocysteine on the pathogenesis of glaucoma, three single nucleotide polymorphisms from two genes involved in the pathway of homocysteine metabolism were genotyped and homocysteine levels were measured.

In total, 156 patients (76 with POAG and 80 with PXFG) from the glaucoma clinic at the University Hospital of Larissa, Greece, were enrolled in the study. The control group consisted of 135 individuals from the cataract clinic of the same hospital. All subjects were unrelated. The study was approved by the local ethics committee and carried out in accordance with the Declaration of Helsinki. All subjects were of Greek nationality and from the same geographic region (central Greece), and had signed their informed consent before entering the study.

All patients underwent a complete ophthalmological examination, including anterior and posterior segment evaluation. The corneal endothelium, iris, iris margins, and the anterior lens surface were evaluated for exfoliative material before and after dilation. Intraocular pressure was measured using a Goldmann applanation tonometer (Haag-Streit, Koeniz-Berne, Switzerland). Gonioscopy was performed to evaluate the depth of the anterior chamber angle and the presence of pseudoexfoliative material and/or hyperpigmentation. Dilated funduscopic examination was performed to evaluate the optic nerve for typical glaucomatous changes. Visual field examination was performed using the 24-2 setting of the Humphrey Field Analyzer automated perimeter and the Swedish Interactive Threshold Algorithm.

Inclusion criteria for POAG patients were intraocular pressure over 22 mmHg on at least two measurements, an open anterior chamber angle determined with gonioscopy, and visual field and optic nerve changes consistent with glaucoma. Presence of exfoliation material in the anterior chamber, together with glaucoma criteria, established the diagnosis of PXFG. Control subjects had no evidence of exfoliative material at the anterior lens capsule or pupillary margin, and had intraocular pressure of less than 22 mmHg. Control subjects had normal visual fields, an open anterior chamber angle, no evidence of glaucomatous changes in the optic disc, and no history of glaucoma or ocular hypertension in first-degree relatives. Subjects with pseudoexfoliation syndrome (with or without ocular hypertension) or ocular hypertension were excluded from the study. The nutritional status of both patients and controls was assessed using the Subjective Global Nutritional Assessment test, according to Detsky et al.[@b28-opth-8-1819] Only subjects classified as "well nourished" were included.

Individuals with systemic conditions known to influence homocysteine levels or using medications or nutritional supplements that interfere with homocysteine metabolism, such as renal disease, B~12~ malabsorption, high alcohol intake, methotrexate, phenytoin, carbamazepine, or fibrate therapy were excluded.[@b29-opth-8-1819]--[@b31-opth-8-1819] Individuals with a history of bilateral cataract extraction, previous intraocular inflammation, or major ocular disease were also excluded.

Fasting plasma homocysteine levels were determined using a commercially available homocysteine enzyme immunoassay kit (Axis^®^; Axis-Shield, Dundee, UK), following the manufacturer's instructions. Homocysteine levels were measured in μmol/L.

Genomic DNA was extracted from peripheral blood leukocytes using a commercially available DNA extraction kit (Qiagen, Valencia, CA, USA) according to the manufacturer's standard protocol. Genotyping was performed using real-time polymerase chain reaction predesigned TaqMan^®^ single nucleotide polymorphism genotyping assays (Applied Biosystems, Foster City, CA, USA). Patients were genotyped for three single nucleotide polymorphisms, ie, two exon *MTHFR* variations, 1298A\>C (rs1801131) and 677C\>T, (rs1801133), and one intron *MTHFD1* variation (rs8006686).

Deviation from Hardy--Weinberg equilibrium was tested on each single nucleotide polymorphism using the chi-squared test in the unaffected population. Single nucleotide polymorphisms were tested for association using the minor allele, as defined by the allele occurring less frequently in the control subjects. Allelic and covariate associations with glaucoma were performed in SAS (version 9.1; Cary, NC, USA) using logistic regression. Age and homocysteine levels were tested for association with glaucoma as continuous variables while sex was tested as dichotomous. Separate analyses were performed assuming additive, dominant, and recessive genetic models for allelic association. Tests for interaction between the genetic variants and homocysteine levels were performed by adding an interaction term to the logistic regression model including both variables. Linkage disequilibrium (*r*^2^) between single nucleotide polymorphisms on the same chromosome was determined using the Haploview program (<http://www.broad.mit.edu/mpg/haploview/>).

Results
=======

Data were available for 291 subjects. Of these, 76 had POAG and 80 had PXFG, and 135 were controls. Subject characteristics are shown in [Table 1](#t1-opth-8-1819){ref-type="table"} and the genotype and allele frequencies in [Table 2](#t2-opth-8-1819){ref-type="table"}. All patients were Caucasian. The average age, proportion of males, and homocysteine levels were similar between the groups ([Table 1](#t1-opth-8-1819){ref-type="table"}) and showed no statistically significant differences ([Table 3](#t3-opth-8-1819){ref-type="table"}). Homocysteine levels were higher in patients as compared with controls, but were not significantly different, although there was a larger difference in homocysteine levels between PXFG and controls (1.1 μmol/L) than between POAG and controls (0.2 μmol/L). Increasing age was associated with an increased risk of PXFG (*P*=0.0021, [Table 2](#t2-opth-8-1819){ref-type="table"}). The two single nucleotide polymorphisms in the *MTHFR* gene (rs1801133 and rs1801131) and the one single nucleotide polymorphism in the *MTHFD1* gene (rs8006686) were in Hardy--Weinberg equilibrium (data not shown). The single nucleotide polymorphisms in the *MTHFR* gene were not in high linkage disequilibrium among the controls (*r*^2^=0.34, [Figure 1](#f1-opth-8-1819){ref-type="fig"}), and had identical linkage disequilibrium in each glaucoma subtype (data not shown). The minor alleles of the *MTHFR* single nucleotide polymorphisms were in a protective direction for POAG, whereas they showed an increased risk for PXFG, but none of these associations reached statistical significance (*P*\>0.05, [Table 2](#t2-opth-8-1819){ref-type="table"}). The minor allele of *MTHFD1*, rs8006686, showed a trend of increased risk for both POAG and PXFG, but this was not statistically significant (*P*\>0.05, [Table 2](#t2-opth-8-1819){ref-type="table"}). No statistically significant interaction was seen between the genetic variants and homocysteine levels (*P*\>0.05, data not shown).

Discussion
==========

The association between plasma homocysteine levels and glaucoma remains inconsistent. In the present study, we did not find an association between single nucleotide polymorphisms 1298A\>C (rs1801131) and 677C\>T (rs1801133) in the *MTHFR* gene and one intron variation (rs8006686) in the *MTHFD1* gene and POAG or PXFG. In addition, no significant difference in plasma homocysteine levels was observed between patients and controls. In accordance with our results, Turaçli et al found no significant association between homocysteine levels and pseudoexfoliation syndrome (PXFS) and PXFG in a cohort of Turkish patients.[@b26-opth-8-1819] Interestingly, a recent study in a Pakistani population reported elevated homocysteine levels and a higher prevalence of the rs1801133 and rs1801131 polymorphisms in patients with primary angle-closure glaucoma, but not in those with POAG.[@b25-opth-8-1819] On the other hand, a number of previous studies have reported that plasma homocysteine was elevated in patients with pseudoexfoliation with or without glaucoma. Two groups of investigators reported elevated plasma homocysteine levels in both POAG and PXFG patients when compared with controls.[@b17-opth-8-1819],[@b18-opth-8-1819],[@b32-opth-8-1819],[@b33-opth-8-1819] Similarly, plasma homocysteine levels were associated with PXFG and PXFS in a number of studies when compared with groups of patients with nonexfoliation or normal controls.[@b19-opth-8-1819],[@b34-opth-8-1819]--[@b37-opth-8-1819] The association between homocysteine levels and PXFG was confirmed by a very recent meta-analysis that included data from 14 studies (485 cases and 456 controls).[@b22-opth-8-1819] Several other groups of investigators did not confirm the association between homocysteine and POAG.[@b20-opth-8-1819],[@b36-opth-8-1819],[@b38-opth-8-1819],[@b39-opth-8-1819] However, a meta-analysis by Xu et al reviewed the results of 12 studies investigating the relationship between homocysteine levels and POAG and concluded that POAG is associated with higher homocysteine levels.[@b21-opth-8-1819]

Regarding the genetic aspect of homocysteine metabolism, no study has found a significant association between single nucleotide polymorphisms in homocysteine metabolism genes and open-angle glaucoma,[@b23-opth-8-1819]--[@b26-opth-8-1819] which is consistent with our results. However, it should be noted that most of the studies tested the rs1801133 polymorphism and only Fan et al included all 17 single nucleotide polymorphisms of the homocysteine metabolism genes.[@b23-opth-8-1819]

In addition to inherited disorders of the homocysteine metabolism enzymes, several known conditions can result in elevated homocysteine levels, including vitamin B~6~ and B~12~ or folic acid deficiency, renal disease, hypothyroidism, advanced age, and smoking. Different dietary habits or lifestyle due to cultural particularities might result in heterogeneous results among distinct ethnic groups. A detailed medical history was taken for both patients and controls, and the Subjective Global Nutritional Assessment test was used to minimize the potential impact of these factors on measured homocysteine values. However, no data were available for smoking status, weight, and physical activity levels, and this was one of the limitations of the study. Additionally, it would be reasonable to assume that variation in the laboratory methods used to determine plasma homocysteine levels might partly explain the inconsistent findings.[@b39-opth-8-1819]

Our study has all the limitations that apply to genetic association studies.[@b40-opth-8-1819],[@b41-opth-8-1819] The sample sizes required to predict association need to be far beyond what is currently available, and any single institution or entity alone would probably not be able to provide a reasonable number of patients. Collaborative studies with large cohorts of patients would be required to provide more power to detect significant relationships. Alternatively, consortia performing gene candidate or genome-wide association studies will be able to replicate the validity of the present findings.

Nevertheless, the present study fulfills the minimum requirements for an association study to be informative. These include controls matched for age and sex, a good scientific rationale, presence of Hardy--Weinberg equilibrium in genotypes, and a similar ethnic background.[@b40-opth-8-1819] In our case, the study population constitutes a very homogeneous Caucasian cohort, as all subjects originate from the central part of our country. In addition, because our hospital is the only tertiary institution covering a rural and urban region with nearly one million inhabitants, and more severe patients are usually referred to us, we cannot exclude the possibility of selection bias.

Conclusion
==========

Neither single nucleotide polymorphisms in the genes involved in the pathway of homocysteine metabolism nor measured homocysteine levels were shown to be associated with either POAG or PFXG in this study cohort.
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###### 

Subject characteristics

  Characteristic                 Controls (n=135)   POAG (n=76)   PXFG (n=80)
  ------------------------------ ------------------ ------------- -------------
  Male (% total)                 73 (54.1%)         43 (56.6%)    52 (65.0%)
  Mean ± SD age, years           71.3±8.6           71.2±9.8      75.0±6.6
  Mean ± SD homocysteine level   16.3±5.7           16.5±6.1      17.4±6.3
  *MTHFR* rs1801131 MAF          G =30.8%           G =29.5%      G =36.5%
  *MTHFR* rs1801133 MAF          A =43.1%           A =41.4%      A =36.8%
  *MTHFD1* rs8006686 MAF         C =21.4%           C =22.5%      C =24.3%

**Abbreviations:** POAG, primary open angle glaucoma; PXFG, pseudoexfoliation glaucoma; SD, standard deviation; MAF, minor allele frequency; *MTHFR, 5,10-methylenetetrahydrofolate reductase; MTHFD1, methylenetetrahydrofolate dehydrogenase*.

###### 

Genotype and allele frequencies

                 Normal   POAG   PXFG                    
  -------------- -------- ------ -------- ----- -------- -----
  ***MTHFR***                                            
  rs1801131                                              
   Genotype                                              
   TT            48.12%   64     50.00%   33    41.89%   31
   GT            42.11%   56     40.91%   27    43.24%   32
   GG            9.77%    13     9.09%    6     14.86%   11
   Total                  133             66             74
   Allele                                                
   T             69.17%   184    70.45%   93    63.51%   94
   G             30.83%   82     29.55%   39    36.49%   54
   Total                  266             132            148
  ***MTHFR***                                            
  rs1801133                                              
   Genotype                                              
   GG            30.00%   39     34.38%   22    40.28%   29
   AG            53.85%   70     48.44%   31    45.83%   33
   AA            16.15%   21     17.19%   11    13.89%   10
   Total                  130             64             72
   Allele                                                
   G             56.92%   148    58.59%   75    63.19%   91
   A             43.08%   112    41.41%   53    36.81%   53
   Total                  260             128            144
  ***MTHFDI***                                           
  rs8006686                                              
   Genotype                                              
   TT            62.60%   82     61.97%   44    56.94%   41
   CT            32.06%   42     30.99%   22    37.50%   27
   CC            5.34%    7      7.04%    5     5.56%    4
   Total                  131             71             72
   Allele                                                
   T             78.63%   206    77.46%   110   75.69%   109
   C             21.37%   56     22.54%   32    24.31%   35
   Total                  262             142            144

**Abbreviations:** POAG, primary open angle glaucoma; PXFG, pseudoexfoliation glaucoma; MTHFR, 5,10-methylenetetrahydrofolate reductase; MTHFD1, methylenet etrahydrofolate dehydrogenase.

###### 

Association results

  Variable              Risk     Model         POAG    PXFG                                             
  --------------------- -------- ------------- ------- ------- ------- -------- ------- ------- ------- --------
  Age                            Continuous    0.998   0.968   1.030   0.9232   1.063   1.022   1.105   0.0021
  Homocysteine levels            Continuous    1.006   0.957   1.057   0.8152   1.034   0.985   1.084   0.1764
  *MTHFR* rs1801131     G        Additive      0.942   0.599   1.481   0.7950   1.278   0.841   1.942   0.2497
  *MTHFR* rs1801131     G        Dominant      0.928   0.514   1.674   0.8027   1.287   0.725   2.283   0.3892
  *MTHFR* rs1801131     G        Recessive     0.923   0.334   2.549   0.8771   1.612   0.683   3.805   0.2761
  *MTHFR* rs1801133     A        Additive      0.929   0.596   1.448   0.7463   0.757   0.491   1.167   0.2078
  *MTHFR* rs1801133     A        Dominant      0.818   0.432   1.548   0.5374   0.635   0.348   1.160   0.1400
  *MTHFR* rs1801133     A        Recessive     1.077   0.484   2.397   0.8552   0.837   0.371   1.891   0.6691
  *MTHFD1* rs8006686    C        Additive      1.065   0.662   1.714   0.7941   1.177   0.730   1.897   0.5033
  *MTHFD1* rs8006686    C        Dominant      1.027   0.566   1.863   0.9305   1.265   0.705   2.272   0.4309
  *MTHFD1* rs8006686    C        Recessive     1.342   0.410   4.393   0.6268   1.042   0.295   3.687   0.9489
  Sex                   Female   Dichotomous   0.904   0.513   1.591   0.7256   0.634   0.358   1.122   0.1176

**Abbreviations:** CI, confidence interval; OR, odds ratio; POAG, primary open angle glaucoma; PXFG, pseudoexfoliation glaucoma; *MTHFR, 5,10-methylenetetrahydrofolate reductase; MTHFD1, methylenetetrahydrofolate dehydrogenase*.
